Skip to content

Combination of chemotherapy and gefitinib as first-line treatment of patients with advanced lung adenocarcinoma and sensitive EGFR mutations: a randomised controlled trial

Combination of chemotherapy and gefitinib as first-line treatment of patients with advanced lung adenocarcinoma and sensitive EGFR mutations: a randomised controlled trial

Status
Recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR-TRC-14004680
Enrollment
Unknown
Registered
2014-05-08
Start date
2011-01-01
Completion date
Unknown
Last updated
2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

lung cancer

Interventions

A:EGFR-TKI
30:TKI??????

Sponsors

Shanghai Chest Hospital
Lead Sponsor

Eligibility

Sex/Gender
Male
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1.Signed informed consent;2.Age >=18 years;3.Histologically documented, unresectable, inoperable, locally advanced, recurrent or metastatic Stage IV Non-Small Cell Lung Cancer (NSCLC);4.A cytologic diagnosis is acceptable (i.e., FNA or pleural fluid cytology);5.Measurable or non-measurable disease;6.Able to comply with study and follow-up procedures.

Exclusion criteria

Exclusion criteria: Evidence of small cell, carcinoid, or mixed small cell/non-small cell histology; Malignancies within 3 years except for adequately treated carcinoma in situ of the cervix or basal or squamous cell skin cancer; Symptomatic or untreated brain metastases; Prior systemic chemotherapy for NSCLC; Prior exposure to agents directed at the HER axis (e.g., ZD1839 [Iressa], C225 [Cetuximab], Trastuzumab [Herceptin]); Unstable systemic disease, including active infection, uncontrolled hypertension, unstable angina, congestive heart failure, or myocardial infarction within 6 months prior to Day 1, or serious cardiac arrhythmia requiring medication (patients with chronic atrial arrhythmia, i.e., atrial fibrillation or paroxysmal supraventricular tachycardia, are eligible); History of other diseases, metabolic dysfunction, physical examination finding, or clinical laboratory finding giving reasonable suspicion of a disease or condition that contraindicates the use of an investigational drug or that might affect the interpretation of the results of the study or render the patient at high risk from treatment complications; Gastrointestinal tract disease resulting in an inability to take oral medication or a requirement for intravenous (IV) alimentation, or prior surgical procedures affecting absorption; Pregnancy or lactation.

Design outcomes

Primary

MeasureTime frame
PF;

Countries

China

Contacts

Public ContactJin Bo
lj991117@163.com+86 13761872187

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026